ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
1-Year Return
26.77%
This Quarter Return
+12.59%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$366M
AUM Growth
+$143M
(+64%)
Cap. Flow
+$97.7M
Cap. Flow
% of AUM
26.67%
Top 10 Holdings %
Top 10 Hldgs %
59.33%
Holding
282
New
118
Increased
36
Reduced
44
Closed
29
Top Buys
| 1 |
Alpha Architect 1-3 Month Box ETF
BOXX
|
$33.9M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$25.5M |
| 3 |
Protagonist Therapeutics
PTGX
|
$16.9M |
| 4 |
Roivant Sciences
ROIV
|
$16.2M |
| 5 |
Cytokinetics
CYTK
|
$15.9M |
Top Sells
| 1 |
Keros Therapeutics
KROS
|
$23.2M |
| 2 |
Viking Therapeutics
VKTX
|
$19.7M |
| 3 |
Royalty Pharma
RPRX
|
$18.2M |
| 4 |
Merck
MRK
|
$7.09M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$6.35M |
Sector Composition
| 1 | Healthcare | 82.64% |
| 2 | Communication Services | 1.24% |
| 3 | Financials | 0.78% |
| 4 | Materials | 0.59% |
| 5 | Consumer Discretionary | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
176
Stoke Therapeutics
STOK
$1.08B
| $39.2K | 0.01% |
+2,900
| New | +$39.2K |
|
177
Magnachip Semiconductor
MX
$106M
| $39.1K | 0.01% |
7,000
| – | – |
|
|
IGMS
178
DELISTED
IGM Biosciences
IGMS
| $38.6K | 0.01% |
+4,000
| New | +$38.6K |
|
|
ASLN
179
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
| $36.5K | 0.01% |
+7,424
| New | +$36.5K |
|
180
89bio
ETNB
$1.28B
| $35.6K | 0.01% |
3,060
+2,630
| +612% | +$30.6K |
|
|
HOOK
181
DELISTED
HOOKIPA Pharma
HOOK
| $35.6K | 0.01% |
+5,000
| New | +$35.6K |
|
182
Neurogene
NGNE
$280M
| $33.6K | 0.01% |
661
-4,744
| -88% | -$241K |
|
183
Rallybio
RLYB
$24.5M
| $33.2K | 0.01% |
+17,942
| New | +$33.2K |
|
184
Terns Pharmaceuticals
TERN
$618M
| $32.8K | 0.01% |
5,000
-8,007
| -62% | -$52.5K |
|
185
Amphastar Pharmaceuticals
AMPH
$1.36B
| $30.7K | 0.01% |
+700
| New | +$30.7K |
|
186
Liquidia Corp
LQDA
$2.48B
| $29.5K | 0.01% |
+2,000
| New | +$29.5K |
|
187
Design Therapeutics
DSGN
$348M
| $29K | 0.01% |
7,200
+5,200
| +260% | +$21K |
|
188
Quince Therapeutics
QNCX
$86.2M
| $28.4K | 0.01% |
+26,829
| New | +$28.4K |
|
189
Savara
SVRA
$619M
| $27.9K | 0.01% |
+5,600
| New | +$27.9K |
|
190
Ventyx Biosciences
VTYX
$185M
| $27.5K | 0.01% |
5,000
-8,000
| -62% | -$44K |
|
191
Perrigo
PRGO
$3.2B
| $25.8K | 0.01% |
+800
| New | +$25.8K |
|
192
NCR Voyix
VYX
$1.74B
| $25.3K | 0.01% |
2,000
| – | – |
|
193
AnaptysBio
ANAB
$590M
| $22.5K | 0.01% |
+1,000
| New | +$22.5K |
|
|
ONCT
194
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| $22.2K | 0.01% |
+2,472
| New | +$22.2K |
|
195
Compass Therapeutics
CMPX
$578M
| $20.2K | ﹤0.01% |
+10,206
| New | +$20.2K |
|
196
Zymeworks
ZYME
$1.07B
| $20K | ﹤0.01% |
+1,900
| New | +$20K |
|
197
NCR Atleos
NATL
$2.93B
| $19.8K | ﹤0.01% |
1,000
| – | – |
|
198
Arrowhead Research
ARWR
$3.87B
| $17.2K | ﹤0.01% |
600
+300
| +100% | +$8.58K |
|
199
PMV Pharmaceuticals
PMVP
$76.3M
| $17K | ﹤0.01% |
+10,000
| New | +$17K |
|
200
AstraZeneca
AZN
$254B
| $13.6K | ﹤0.01% |
+200
| New | +$13.6K |
|